ESTRO 2024 - Abstract Book

S2035

Clinical - Paediatric

ESTRO 2024

Figure 2 Forest plot of pooled EFS, PFS, RFS and DFS grouped by use of chemotherapy

Conclusion:

In the current analysis, 5-year PFS and OS were 77% and 84%, respectively. These survival metrics have remained largely unchanged during the past two decades, despite the many strategies introduced in the radiotherapy delivery to increase survival and to mitigate toxicity. The survival has only been affected by the introduction of chemotherapy. This motivates further improvement of the radiotherapy, e.g. hippocampus sparing proton radiotherapy, as long as adequate target coverage is maintained [26, 27]. There is still limited outcomes data reported on molecular subgroups, and to reveal potential interactions with radiation dose/technology will require more detailed and additional analyses. The present pooled analyses showed no association between survival and dose to the CS-axis and/or the primary tumor. However, it is probable that a specific dose-response relationship exists for each molecular subgroup.

*Photons (cranial) + electrons (spinal)

Keywords: Medulloblastoma, systematic review, CSI

References:

[1] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

[2] Benk V, Bouhnik H, Raquin MA, Kalifa C, Habrand JL. Quality control of low dose craniospinal irradiation for low risk medulloblastoma. Brit J Radiol. 1995;68:1009-13.